MedTrace Logo

Human Mass Balance and Biotransformation Study of [14C]TNP-2198

NCT06137573 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-11-18

No results posted yet for this study

Summary

The purpose of the study is to analyze absorption, metabolism, excretion, mass balance and biotransformation after a single oral dose of \[14C\]TNP-2198 in healthy male participants

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

[14C]TNP-2198

600mg suspension containing 150μCi of \[14C\] TNP-2198

Sponsors & Collaborators

  • TenNor Therapeutics (Suzhou) Limited

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-12
Primary Completion
2022-09-01
Completion
2022-09-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06137573 on ClinicalTrials.gov